This initial 6-variable analysis included secondary AML, ELN risk category, FLT3/TP53/RUNX1 mutation, the use of intensive 7 + 3 induction chemotherapy, stem cell transplant, and MRD detected by NGS. This evidence concerns the gene RUNX1 and acute myeloid leukemia.